IMAX
IMAX Corporation NYSE Listed Jun 10, 1994$44.33
+0.09%
vs $44.29
Mkt Cap $2.5B
52w Low $24.51
100.0% of range
52w High $44.33
50d MA $37.67
200d MA $36.05
P/E (TTM)
70.4x
EV/EBITDA
19.3x
P/B
5.6x
Debt/Equity
0.9x
ROE
10.3%
P/FCF
20.7x
RSI (14)
78.80
ATR (14)
$1.45
Beta
0.40
50d MA
$37.67
200d MA
$36.05
Avg Volume
1.1M
IMAX Corporation, together with its subsidiaries, operates as an entertainment technology company worldwide. It offers cinematic solution through proprietary software, theater architecture, intellectual property, and specialized equipment. The company offers IMAX Digital Re-Mastering (DMR), a proprietary technology that digitally enhances the image resolution, visual clarity, and sound quality of motion picture films for projection on IMAX screens; IMAX theater systems to exhibitor customers through sales, leases, and joint revenue sharing arrangements; and digital projection systems. It also provides preventative and emergency maintenance services to IMAX network; distributes large-format documentary films; film post-production and quality control services for large-format films, and digital post-production services; owns and operates IMAX theaters; and rents 2D and 3D large-format film and digital cameras, as well as offers production advice and technical assistance services to documentary and Hollywood filmmakers. The company markets its theater systems through a direct sales force and marketing staff to science and natural history museums, zoos, aquaria, and other educational and cultural centers, as well as theme parks, private home theaters, tourist destination sites, fairs, and expositions. It owns or otherwise has rights to trademarks and trade names, which include IMAX, IMAX Dome, IMAX 3D, IMAX 3D Dome, Experience It in IMAX, The IMAX Experience, An IMAX Experience, An IMAX 3D Experience, IMAX DMR, DMR, IMAX Enhanced, IMAX nXos, and Films To The Fullest. As of December 31, 2021, the company had a network of 1,683 IMAX theater systems comprising 1,599 commercial multiplexes, 12 commercial destinations, and 72 institutional facilities operating in 87 countries and territories. IMAX Corporation was founded in 1967 and is headquartered in Mississauga, Canada.
2525 Speakman Drive · Mississauga, ON L5K 1B1 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | AMC | 0.15 | 0.17 | +13.3% | 38.02 | -6.6% | -4.0% | -3.5% | +1.4% | -0.1% | -0.1% | — |
| Feb 25, 2026 | AMC | 0.43 | 0.58 | +34.9% | 36.52 | +4.0% | +14.4% | +2.5% | -1.9% | -2.0% | -0.1% | — |
| Oct 23, 2025 | AMC | 0.35 | 0.47 | +34.1% | 32.44 | +0.4% | -2.3% | +1.6% | +1.7% | +0.4% | -1.5% | — |
| Jul 24, 2025 | AMC | 0.19 | 0.26 | +36.8% | 28.29 | +1.0% | -5.1% | +0.4% | -3.6% | -1.3% | +0.5% | — |
| Apr 23, 2025 | AMC | 0.11 | 0.13 | +18.2% | 24.09 | +3.8% | -3.3% | +2.6% | +0.3% | +1.8% | -0.3% | — |
| Feb 19, 2025 | AMC | 0.29 | 0.27 | -6.9% | 27.22 | -1.7% | -1.1% | -3.3% | +0.9% | +0.5% | -2.6% | — |
| Oct 30, 2024 | AMC | 0.22 | 0.35 | +59.1% | 21.68 | +1.5% | +12.1% | -1.0% | +0.5% | +0.3% | +1.9% | — |
| Jul 25, 2024 | AMC | 0.06 | 0.18 | +200.0% | 19.40 | +2.3% | +3.6% | -1.0% | +3.8% | +2.2% | +0.4% | — |
| Apr 25, 2024 | AMC | 0.10 | 0.15 | +50.0% | 17.46 | -0.2% | -1.8% | -0.4% | -6.3% | +1.1% | +1.2% | — |
| Feb 27, 2024 | AMC | 0.10 | 0.17 | +70.0% | 15.79 | +7.3% | +11.1% | -2.3% | -1.5% | -1.2% | +1.7% | — |
| Oct 25, 2023 | AMC | 0.21 | 0.35 | +66.7% | 18.11 | +1.2% | +0.7% | -1.6% | +1.6% | -0.1% | -0.7% | — |
| Jul 26, 2023 | AMC | 0.17 | 0.26 | +52.9% | 17.38 | +13.7% | +8.5% | -1.1% | -1.2% | -0.1% | +1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Macquarie | Maintains | Outperform → Outperform | — | $38.02 | $35.52 | -6.6% | -4.0% | -3.5% | +1.4% | -0.1% | -0.1% |
| May 1 | Barrington Research | Maintains | Outperform → Outperform | — | $38.02 | $35.52 | -6.6% | -4.0% | -3.5% | +1.4% | -0.1% | -0.1% |
| May 1 | JP Morgan | Maintains | Overweight → Overweight | — | $38.02 | $35.52 | -6.6% | -4.0% | -3.5% | +1.4% | -0.1% | -0.1% |
| Apr 23 | Wedbush | Maintains | Outperform → Outperform | — | $36.22 | $36.05 | -0.5% | +1.1% | -0.4% | +1.8% | -0.4% | +0.7% |
| Apr 20 | Rosenblatt | Maintains | Buy → Buy | — | $35.09 | $35.00 | -0.3% | +2.5% | -0.6% | +1.3% | +1.1% | -0.4% |
| Apr 8 | Seaport Global | Maintains | Buy → Buy | — | $38.80 | $39.67 | +2.2% | -1.5% | -0.9% | -0.0% | -2.4% | -0.3% |
| Mar 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $42.83 | $42.58 | -0.6% | -1.9% | -2.0% | -0.1% | -1.7% | +0.8% |
| Feb 26 | Benchmark | Maintains | Buy → Buy | — | $36.52 | $37.98 | +4.0% | +14.4% | +2.5% | -1.9% | -2.0% | -0.1% |
| Feb 26 | Macquarie | Maintains | Outperform → Outperform | — | $36.52 | $37.98 | +4.0% | +14.4% | +2.5% | -1.9% | -2.0% | -0.1% |
| Feb 26 | Rosenblatt | Maintains | Buy → Buy | — | $36.52 | $37.98 | +4.0% | +14.4% | +2.5% | -1.9% | -2.0% | -0.1% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $36.52 | $37.98 | +4.0% | +14.4% | +2.5% | -1.9% | -2.0% | -0.1% |
| Feb 24 | Rosenblatt | Maintains | Buy → Buy | — | $36.79 | $36.76 | -0.1% | +0.1% | -0.8% | +14.4% | +2.5% | -1.9% |
| Feb 23 | Wedbush | Maintains | Outperform → Outperform | — | $37.81 | $37.93 | +0.3% | -2.7% | +0.1% | -0.8% | +14.4% | +2.5% |
| Jan 26 | Barrington Research | Maintains | Outperform → Outperform | — | $34.61 | $34.85 | +0.7% | +0.4% | +0.0% | -0.7% | -0.4% | +1.6% |
| Jan 15 | Macquarie | Maintains | Outperform → Outperform | — | $35.07 | $35.11 | +0.1% | +3.5% | +3.1% | +0.5% | -2.6% | -3.4% |
| Dec 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $37.42 | $38.00 | +1.6% | +0.1% | -0.5% | +0.0% | +0.4% | +0.7% |
| Dec 15 | JP Morgan | Upgrade | Neutral → Overweight | — | $38.17 | $39.28 | +2.9% | +2.3% | -3.2% | -1.0% | +0.1% | -0.5% |
| Dec 8 | Barrington Research | Maintains | Outperform → Outperform | — | $35.71 | $36.42 | +2.0% | +7.8% | -1.2% | +0.2% | +0.5% | -0.3% |
| Dec 8 | Benchmark | Maintains | Buy → Buy | — | $35.71 | $36.42 | +2.0% | +7.8% | -1.2% | +0.2% | +0.5% | -0.3% |
| Dec 8 | Wedbush | Maintains | Outperform → Outperform | — | $35.71 | $36.42 | +2.0% | +7.8% | -1.2% | +0.2% | +0.5% | -0.3% |
| Dec 8 | Rosenblatt | Maintains | Buy → Buy | — | $35.71 | $36.42 | +2.0% | +7.8% | -1.2% | +0.2% | +0.5% | -0.3% |
| Nov 25 | Goldman Sachs | Upgrade | Sell → Neutral | — | $36.00 | $36.52 | +1.4% | +0.1% | +2.4% | +0.6% | -0.7% | -3.3% |
| Oct 24 | Barrington Research | Maintains | Outperform → Outperform | — | $32.44 | $32.56 | +0.4% | -2.3% | +1.6% | +1.7% | +0.4% | -1.5% |
| Oct 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $32.44 | $32.56 | +0.4% | -2.3% | +1.6% | +1.7% | +0.4% | -1.5% |
| Oct 24 | Rosenblatt | Maintains | Buy → Buy | — | $32.44 | $32.56 | +0.4% | -2.3% | +1.6% | +1.7% | +0.4% | -1.5% |
| Oct 24 | JP Morgan | Maintains | Neutral → Neutral | — | $32.44 | $32.56 | +0.4% | -2.3% | +1.6% | +1.7% | +0.4% | -1.5% |
| Oct 23 | Barrington Research | Maintains | Outperform → Outperform | — | $32.06 | $32.63 | +1.8% | +1.2% | -2.3% | +1.6% | +1.7% | +0.4% |
| Oct 14 | Roth Capital | Maintains | Buy → Buy | — | $31.09 | $31.14 | +0.2% | +0.7% | +1.3% | -0.5% | +2.1% | +0.7% |
| Oct 9 | JP Morgan | Maintains | Neutral → Neutral | — | $32.22 | $32.35 | +0.4% | -1.1% | -2.1% | -0.4% | +0.7% | +1.3% |
| Oct 9 | Rosenblatt | Maintains | Buy → Buy | — | $32.22 | $32.35 | +0.4% | -1.1% | -2.1% | -0.4% | +0.7% | +1.3% |
| Sep 23 | Barrington Research | Maintains | Outperform → Outperform | — | $32.66 | $32.71 | +0.2% | -0.1% | -1.1% | +0.4% | +0.6% | -0.8% |
| Sep 22 | Wedbush | Maintains | Outperform → Outperform | — | $31.96 | $32.09 | +0.4% | +2.2% | -0.1% | -1.1% | +0.4% | +0.6% |
| Sep 19 | Barrington Research | Maintains | Outperform → Outperform | — | $32.31 | $32.31 | +0.0% | -1.1% | +2.2% | -0.1% | -1.1% | +0.4% |
| Jul 25 | Benchmark | Maintains | Buy → Buy | — | $28.29 | $28.57 | +1.0% | -5.1% | +0.4% | -3.6% | -1.3% | +0.5% |
| Jul 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $28.29 | $28.57 | +1.0% | -5.1% | +0.4% | -3.6% | -1.3% | +0.5% |
| Jul 25 | Wedbush | Maintains | Outperform → Outperform | — | $28.29 | $28.57 | +1.0% | -5.1% | +0.4% | -3.6% | -1.3% | +0.5% |
| Jul 25 | Rosenblatt | Maintains | Buy → Buy | — | $28.29 | $28.57 | +1.0% | -5.1% | +0.4% | -3.6% | -1.3% | +0.5% |
| Jul 24 | Barrington Research | Maintains | Outperform → Outperform | — | $29.03 | $29.13 | +0.3% | -2.5% | -5.1% | +0.4% | -3.6% | -1.3% |
| Jul 11 | Rosenblatt | Maintains | Buy → Buy | — | $26.17 | $26.40 | +0.9% | +2.9% | +3.6% | -0.1% | +1.5% | +0.9% |
| Jul 9 | Roth Capital | Maintains | Buy → Buy | — | $26.90 | $26.78 | -0.4% | -2.2% | -0.5% | +2.9% | +3.6% | -0.1% |
| Jun 16 | Rosenblatt | Maintains | Buy → Buy | — | $28.88 | $28.90 | +0.1% | +1.2% | -0.3% | +0.1% | -2.6% | -2.2% |
| Jun 13 | Roth Capital | Maintains | Buy → Buy | — | $28.60 | $28.49 | -0.4% | +1.0% | +1.2% | -0.3% | +0.1% | -2.6% |
| Apr 25 | Macquarie | Maintains | Outperform → Outperform | — | $23.29 | $22.81 | -2.1% | +2.6% | +0.3% | +1.8% | -0.3% | -0.7% |
| Apr 24 | Barrington Research | Maintains | Outperform → Outperform | — | $24.09 | $25.00 | +3.8% | -3.3% | +2.6% | +0.3% | +1.8% | -0.3% |
| Apr 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $24.09 | $25.00 | +3.8% | -3.3% | +2.6% | +0.3% | +1.8% | -0.3% |
| Apr 24 | Rosenblatt | Maintains | Buy → Buy | — | $24.09 | $25.00 | +3.8% | -3.3% | +2.6% | +0.3% | +1.8% | -0.3% |
| Apr 11 | JP Morgan | Maintains | Neutral → Neutral | — | $22.03 | $22.09 | +0.3% | -2.7% | +0.9% | +0.1% | +0.5% | +3.1% |
| Apr 10 | Benchmark | Maintains | Buy → Buy | — | $23.44 | $22.60 | -3.6% | -6.0% | -2.7% | +0.9% | +0.1% | +0.5% |
| Apr 10 | Rosenblatt | Maintains | Buy → Buy | — | $23.44 | $22.60 | -3.6% | -6.0% | -2.7% | +0.9% | +0.1% | +0.5% |
| Feb 21 | JP Morgan | Maintains | Neutral → Neutral | — | $26.93 | $27.20 | +1.0% | -3.3% | +0.9% | +0.5% | -2.6% | -1.4% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | GELFOND RICHARD L | Chief Executive Officer | Sell | 8,943 | $37.33 | $334K | 765,002 | +0.73% | +2.19% |
8-K
IMAX Corporation -- 8-K Filing
IMAX shareholders approved the advisory say-on-pay vote on executive compensation, signaling investor support for the company's current NEO compensation structure and policies.
Jun 11
8-K · 5.02
!!! Very High
Unknown — 8-K Item 5.02: Executive Change
IMAX announced an executive change, which could signal leadership transition or strategy shifts; investors should monitor earnings guidance and operational continuity statements in follow-up disclosures.
Apr 17
8-K · 5.02
!!! Very High
Imax Corp -- 8-K 5.02: Executive Change
Robert D. Lister's appointment as interim principal executive officer at IMAX signals potential leadership transition uncertainty, likely prompting investor scrutiny of strategic direction and operational continuity.
Apr 17
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
CEO Richard Gelfond's temporary medical leave due to pneumonia creates leadership uncertainty and may delay strategic decisions, potentially pressuring IMAX stock until his return timeline clarifies.
Mar 30
8-K
Imax Corp -- 8-K Filing
IMAX projects record $1.4 billion global box office in 2026 with 12+ filmed-for-IMAX releases, signaling strong theatrical demand and expanding market share opportunities for investors.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Orbis Allan Gray Ltd | 5,151,721 | $196M | — | Mar 2026 |
| 2 | Fmr Llc | 3,117,374 | $118M | Reduced | Mar 2026 |
| 3 | Congress Asset Management Co | 1,510,375 | $57M | New | Mar 2026 |
| 4 | Victory Capital Management Inc | 1,091,223 | $41M | Reduced | Mar 2026 |
| 5 | Jpmorgan Chase & Co | 970,570 | $36M | Added | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 691,474 | $26M | Added | Mar 2026 |
| 7 | Nuveen, Llc | 661,544 | $25M | Added | Mar 2026 |
| 8 | Morgan Stanley | 661,690 | $24M | Reduced | Dec 2025 |
| 9 | Primecap Management Co/ca/ | 535,402 | $20M | Reduced | Mar 2026 |
| 10 | Marshall Wace, Llp | 528,382 | $20M | Reduced | Mar 2026 |
| 11 | Pembroke Management, Ltd | 487,918 | $19M | Reduced | Mar 2026 |
| 12 | Vanguard Portfolio Management Llc | 483,221 | $18M | New | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 424,105 | $16M | Reduced | Mar 2026 |
| 14 | Axiom Investors Llc /de | 387,670 | $15M | New | Mar 2026 |
| 15 | Marsico Capital Management Llc | 387,367 | $15M | Reduced | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 385,836 | $15M | New | Mar 2026 |
| 17 | Invesco Ltd. | 367,731 | $14M | Added | Mar 2026 |
| 18 | Qube Research & Technologies Ltd | 335,243 | $13M | Added | Mar 2026 |
| 19 | Renaissance Group Llc | 321,993 | $12M | Added | Mar 2026 |
| 20 | Northern Trust Corp | 301,559 | $11M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.46B
Enterprise Value
$2.56B
P/E (TTM)
70.37x
Forward P/E
26.31x
PEG Ratio
1.74x
P/B
5.56x
P/S
6.00x
P/FCF
20.71x
EV/EBITDA
19.26x
Shares Out
55.5M
Financials (TTM)
Revenue
$410.2M
Net Income
$34.9M
EBITDA
$133.1M
Free Cash Flow
$118.9M
Op Cash Flow
$127.1M
EPS Basic
$0.65
EPS Diluted
$0.63
EPS Forward
$1.69
Gross Margin
57.9%
Op Margin
23.3%
Net Margin
8.5%
Balance Sheet
Total Assets
$894.0M
Total Liab.
$466.3M
Total Equity
$427.7M
Cash
$151.2M
LT Debt
$251.8M
Book Value/Sh
$7.97
Debt/Equity
0.88x
Current Ratio
1.67
Quick Ratio
1.51
Returns & Growth
ROE
10.3%
ROA
3.9%
ROIC
9.4%
Rev Growth YoY
+16.5%
EPS Growth YoY
+32.6%
Price Returns
2W
+16.5%
1M
+4.4%
3M
-7.4%
6M
+7.0%
12M
+42.5%
Technicals
52W High
$44.33
52W Low
$24.51
50d MA
$37.67
200d MA
$36.05
RSI (14)
78.80
ATR (14)
$1.45
Beta
0.40
Avg Volume
1.1M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$42.33
High
$47.00
Low
$34.00
Median
$42.50
Data updated apr 25, 2026 3:15pm
· Source: financialmodelingprep.com